脊柱关节炎的联合治疗

Combination therapies in spondyloarthropathies.

作者信息

Calgüneri Meral, Cobankara Veli, Oztürk M Akif, Ertenli Ihsan, Kiraz Sedat, Apraş Sule

机构信息

Department of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey.

出版信息

Kobe J Med Sci. 2004 Jan;50(1-2):31-7.

PMID:15659875

Abstract

OBJECTIVES

To compare the efficacy and tolerability of single-agent sulfasalazine (SSZ) with combination therapies composed of SSZ and methotrexate (MTX) and SSZ, MTX and hydroxychloroquine (HCQ) in active spondyloarthropathy (SpA) patients with peripheral arthritis.

METHODS

One hundred and fifty SpA patients with peripheral arthritis (male/ female: 92/58) who were treated in our clinic between 1994 and 1998 were enrolled in this trial. Patients treated with SSZ alone (1-3 gr/day) were included in Group I, patients treated with combination of SSZ (1-3 gr/day) and MTX (7.5-15 mg/week) in Group II, and patients treated with combination of SSZ (1-3 gr/day), MTX (7.5-15 mg/week) and HCQ (200 mg/day) in Group III. Forty-eight patients in Group I, 45 patients in Group II and III were eligible for statistical analysis at the end of study.

RESULTS

The combination of MTX, SSZ, and HCQ, and the combination of MTX and SSZ were more effective regarding the clinical and laboratory parameters than SSZ alone (p<0.05). Moreover, the combination of MTX, SSZ, and HCQ was more effective than the combination of MTX and SSZ (p<0.05).

CONCLUSION

Combination therapies seem to be more effective and no more toxic than monotherapy in SpA patients with peripheral arthritis.

摘要

目的

比较单药柳氮磺胺吡啶（SSZ）与由SSZ和甲氨蝶呤（MTX）以及SSZ、MTX和羟氯喹（HCQ）组成的联合疗法，在患有外周关节炎的活动性脊柱关节炎（SpA）患者中的疗效和耐受性。

方法

1994年至1998年在我们诊所接受治疗的150例患有外周关节炎的SpA患者（男/女：92/58）纳入本试验。单独接受SSZ治疗（1 - 3克/天）的患者纳入第一组，接受SSZ（1 - 3克/天）和MTX（7.5 - 15毫克/周）联合治疗的患者纳入第二组，接受SSZ（1 - 3克/天）、MTX（7.5 - 15毫克/周）和HCQ（200毫克/天）联合治疗的患者纳入第三组。研究结束时，第一组48例患者、第二组和第三组各45例患者符合统计分析条件。